OAB-018: From CARDAMON to CoMMpass: a mutational signature that predicts carfilzomib-specific outcomes in myeloma
Ieuan Walker(King's College London), Michael Chapman(Dartmouth College), Daria Galas‐Filipowicz(CRUK Lung Cancer Centre of Excellence), Evie Fitzsimons, James D. Cavenagh(National Health Service), Tushhar Dadaga(Cancer Research UK), Javier Herrero(London Cancer), Laura Clifton‐Hadley(Cancer Research UK), Ceri Bygrave(Cardiff and Vale University Health Board), Matthew Streetly(King's College - North Carolina), Gavin Pang(Cancer Research UK), Roger G. Owen(Leeds Teaching Hospitals NHS Trust), Venetia D’Arcy, William W. Wilson(Dakota State University), Kwee Yong(CRUK Lung Cancer Centre of Excellence), Karthik Ramasamy(Oxford University Hospitals NHS Trust), Richard G. Jenner(Cancer Research UK), Rakesh Popat(University College London Hospitals NHS Foundation Trust), Ruth de Tute(Leeds Teaching Hospitals NHS Trust), Marquita Camilleri(University College London Hospitals NHS Foundation Trust), Sumaiya Kamora(Cancer Research UK), Garima Khandelwal(Cancer Institute (WIA)), Selina J Chavda(University College London), Reuben Benjamin(King's College London)
Cited by 0
Related Papers
An integrated encyclopedia of DNA elements in the human genome
|Nature|2012|19.6k
An integrated encyclopedia of DNA elements in the human genome
|The Journal of the American Medical Association (JAMA) Network (American Medical Association)|2012|2.8k
High-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue for Multiple Myeloma
|New England Journal of Medicine|2003|1.8k
Teclistamab in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2022|1.2k